Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants

Area of Science:

• Pediatric Pharmacology
• Vascular Biology
• Neonatal Medicine

Background:

• Vascular anomalies in neonates can cause life-threatening airway compromise.
• Early medical therapy is crucial for managing these conditions.
• Current sirolimus dosing guidelines are not established for neonates.

Purpose of the Study:

• To evaluate the safety and efficacy of a modified sirolimus dosing regimen in neonates with complicated vascular anomalies.
• To establish appropriate dosing guidelines for sirolimus in very young infants.

Main Methods:

• Retrospective review of six neonates (mean age 14.8 days) treated with a modified sirolimus dosing regimen.
• Monitoring of sirolimus serum concentrations to ensure therapeutic levels and avoid supratherapeutic levels.

Main Results:

• Standard sirolimus dosing resulted in supratherapeutic levels in neonates.
• The modified dosing regimen achieved safe and therapeutic sirolimus concentrations in the study population.
• No adverse events were reported during the treatment period.

Conclusions:

• Modified sirolimus dosing is safe and effective for neonates with complicated vascular anomalies.
• Sirolimus, when properly dosed, is a viable and potentially lifesaving treatment for this population.
• Further research is needed to establish definitive dosing guidelines for neonatal sirolimus therapy.